Search Results - "Salvagni, Stefania"

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort by Ready, Neal E, Ott, Patrick A, Hellmann, Matthew D, Zugazagoitia, Jon, Hann, Christine L, de Braud, Filippo, Antonia, Scott J, Ascierto, Paolo A, Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K, Spigel, David R

“…Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and…”
Get more information

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study by Santoro, Armando, MD, Rimassa, Lorenza, Dr, Borbath, Ivan, MD, Daniele, Bruno, MD, Salvagni, Stefania, MD, Van Laethem, Jean Luc, Prof, Van Vlierberghe, Hans, MD, Trojan, Jörg, Prof, Kolligs, Frank T, Prof, Weiss, Alan, Prof, Miles, Steven, MD, Gasbarrini, Antonio, Prof, Lencioni, Monica, MD, Cicalese, Luca, MD, Sherman, Morris, MD, Gridelli, Cesare, MD, Buggisch, Peter, MD, Gerken, Guido, Prof, Schmid, Roland M, Prof, Boni, Corrado, MD, Personeni, Nicola, MD, Hassoun, Ziad, MD, Abbadessa, Giovanni, MD, Schwartz, Brian, MD, Von Roemeling, Reinhard, MD, Lamar, Maria E, BA, Chen, Yinpu, PhD, Porta, Camillo, MD

“…Summary Background Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising antitumour activity in hepatocellular carcinoma as monotherapy…”
Get full text

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report by Gelsomino, Francesco, Di Federico, Alessandro, Tardio, Maria Lucia, Grilli, Giada, D’Errico, Antonietta, Ardizzoni, Andrea, Salvagni, Stefania

“…Summary Introduction.  The combination of BRAF and MEK inhibitors has deeply changed the treatment of BRAF V600- mutant non-small cell lung cancer patients…”
Get full text

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer by CORTES, Javier, FUMOLEAU, Pierre, SALVAGNI, Stefania, SERVENT, Veronique, GIANNI, Luca, SCALTRITI, Maurizio, ROSS, Graham A, DIXON, Joanna, SZADO, Tania, BASELGA, José, VALERIA BIANCHI, Giulia, PETRELLA, Teresa M, GELMON, Karen, PIVOT, Xavier, VERMA, Shailendra, ALBANELL, Joan, CONTE, Pierfranco, LLUCH, Ana

“…The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2)…”
Get full text

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer by GIANNI, Luca, LLADO, Anna, HERSBERGER, Veronica, BASELGA, José, BIANCHI, Giulia, CORTES, Javier, KELLOKUMPU-LEHTINEN, Pirkko-Liisa, CAMERON, David A, MILES, David, SALVAGNI, Stefania, WARDLEY, Andrew, GOEMINNE, Jean-Charles

“…Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to…”
Get full text

Clinical activity of CC‐90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies by Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, Braud, Filippo, Villambrosia, Sonia Gonzalez, Martin‐Romano, Patricia, Baudin, Eric, Arias, Marina, Alvaro, Juan, Parra‐Palau, Josep L., Sánchez‐Pérez, Tania, Aronchik, Ida, Filvaroff, Ellen H., Lamba, Manisha, Nikolova, Zariana, Bono, Johann S.

“…Background CC‐90011 is an oral, potent, selective, reversible inhibitor of lysine‐specific demethylase 1 (LSD1) that was well tolerated, with encouraging…”
Get full text

Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment by Negri, Francesca V., Dal Bello, Barbara, Porta, Camillo, Campanini, Nicoletta, Rossi, Sandro, Tinelli, Carmine, Poggi, Guido, Missale, Gabriele, Fanello, Silvia, Salvagni, Stefania, Ardizzoni, Andrea, Maria, Silini Enrico

“…Background & Aims The study aimed to evaluate the tissue expression of molecules involved in intracellular signalling pathways as predictors of response to…”
Get full text

Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer by Parisi, Claudia, Lamberti, Giuseppe, Zompatori, Maurizio, Gelsomino, Francesco, Salvagni, Stefania, Sperandi, Francesca, Ardizzoni, Andrea

“…Non-small cell lung cancer (NSCLC) can be associated with pulmonary cystic airspaces (pCAs). pCAs are radiologically classified into four types based on…”
Get full text

Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ care by Massari, Francesco, Mollica, Veronica, Salvagni, Stefania, Tognetto, Michele, Ardizzoni, Andrea

“…According to the WHO, as of 26 April 2020, there are 2,804,796 confirmed cases of coronavirus disease 2019 (COVID-19) and 193,722 confirmed death worldwide…”
Get full text

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia by Gatti, Milo, Raschi, Emanuel, Poluzzi, Elisabetta, Martignani, Cristian, Salvagni, Stefania, Ardizzoni, Andrea, Diemberger, Igor

“…Purpose of Review Cardiotoxicity by anticancer agents has emerged as a multifaceted issue and is expected to affect both mortality and morbidity. This review…”
Get full text

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma by Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Isambert, Nicolas, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, Martin-Romano, Patricia, Baudin, Eric, Arias, Marina, Mora, Sheila, de Alvaro, Juan, Di Martino, Jorge, Parra-Palau, Josep L, Sánchez-Pérez, Tania, Aronchik, Ida, Filvaroff, Ellen H, Lamba, Manisha, Nikolova, Zariana, de Bono, Johann S

“…Lysine-specific demethylase 1 (LSD1) is implicated in multiple tumor types, and its expression in cancer stem cells is associated with chemoresistance…”
Get full text

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification by Angevin, Eric, Spitaleri, Gianluca, Rodon, Jordi, Dotti, Katia, Isambert, Nicolas, Salvagni, Stefania, Moreno, Victor, Assadourian, Sylvie, Gomez, Corinne, Harnois, Marzia, Hollebecque, Antoine, Azaro, Analia, Hervieu, Alice, Rihawi, Karim, De Marinis, Filippo

“…Dysregulated MET signalling is implicated in oncogenesis. The safety and preliminary efficacy of a highly selective MET kinase inhibitor (SAR125844) was…”
Get full text

Pain Outcomes in Patients With Advanced Breast Cancer and Bone Metastases: Results From a Randomized, Double-Blind Study of Denosumab and Zoledronic Acid by CLEELAND, Charles S, BODY, Jean-Jacques, LIPTON, Allan, DE BOER, Richard, SALVAGNI, Stefania, TOSELLO OLIVEIRA, Celia, YI QIAN, QI JIANG, DANSEY, Roger, BRAUN, Ada, CHUNG, Karen, STOPECK, Alison, VON MOOS, Roger, FALLOWFIELD, Lesley, MATHIAS, Susan D, PATRICK, Donald L, CLEMONS, Mark, TONKIN, Katia, MASUDA, Norikazu

“…In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases…”
Get full text

Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins by Rihawi, Karim, Cinausero, Marika, Fiorentino, Michelangelo, Salvagni, Stefania, Brocchi, Stefano, Ardizzoni, Andrea

Get more information

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study by Ahn, Myung-Ju, Tanaka, Kentaro, Paz-Ares, Luis, Cornelissen, Robin, Girard, Nicolas, Pons-Tostivint, Elvire, Vicente Baz, David, Sugawara, Shunichi, Cobo, Manuel, Pérol, Maurice, Mascaux, Céline, Poddubskaya, Elena, Kitazono, Satoru, Hayashi, Hidetoshi, Hong, Min Hee, Felip, Enriqueta, Hall, Richard, Juan-Vidal, Oscar, Brungs, Daniel, Lu, Shun, Garassino, Marina, Chargualaf, Michael, Zhang, Yong, Howarth, Paul, Uema, Deise, Lisberg, Aaron, Sands, Jacob

“…The randomized, open-label, global phase III TROPION-Lung01 study compared the efficacy and safety of datopotamab deruxtecan (Dato-DXd) versus docetaxel in…”
Get full text

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib by Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Salvagni, Stefania, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Trojan, Jörg, De Toni, Enrico N, Weiss, Alan, Miles, Steven, Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E, Wang, Yunxia, Shuster, Dale, Schwartz, Brian E, Santoro, Armando

“…ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It…”
Get full text

Activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor‐prognostic untreated diffuse large B‐cell non‐Hodgkin lymphoma by Musolino, Antonino, Boggiani, Daniela, Panebianco, Michele, Vasini, Giovanna, Salvagni, Stefania, Franciosi, Vittorio, Ardizzoni, Andrea

“…BACKGROUND: This study was designed to assess the activity and safety of dose‐adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone…”
Get full text

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer by Bianchi, Giulia, Loibl, Sibylle, Zamagni, Claudio, Salvagni, Stefania, Raab, Guenter, Siena, Salvatore, Laferriere, Nicole, Peña, Carol, Lathia, Chetan, Bergamini, Loredana, Gianni, Luca

“…This trial was conducted to assess the efficacy and safety of sorafenib in patients with metastatic breast cancer. In this multinational, open-label phase II…”
Get full text

Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors by De Braud, Filippo G., Machiels, Jean-Pascal H., Tiseo, Marcello, Rottey, Sylvie, Duca, Matteo, Laruelle, Marie, Salvagni, Stefania, Lapeire, Lore, Manfreda, Laura, Veau, Céline, Fischer, Daniela, Ould-Kaci, Mahmoud

“…Abstract only…”
Get full text

A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma by Rimassa, Lorenza, Pressiani, Tiziana, Boni, Corrado, Carnaghi, Carlo, Rota Caremoli, Elena, Fagiuoli, Stefano, Foa, Paolo, Salvagni, Stefania, Cortesi, Enrico, Chiara Tronconi, Maria, Personeni, Nicola, Bozzarelli, Silvia, Chiara Banzi, Maria, Fanello, Silvia, Romano Lutman, Fabio, Giordano, Laura, Santoro, Armando

“…Background. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher…”
Get full text